• Tactile Medical’s third-quarter 2026 net income fell 12% year-over-year to $7.2 million.
• Total revenue rose 7% to $91.9 million, while lymphedema revenue climbed 13% to $81.8 million year-over-year.
• The FDA expanded clearance for the LymphaTech 3D Scanner to aid lymphedema assessment.
• Full-year 2026 revenue guidance remained $360 million to $366 million, representing expected growth of 9% to 11%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tactile Systems Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-121315), on November 02, 2026, and is solely responsible for the information contained therein.